Latest Talizumab Stories
Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc.
Houston Allergy & Asthma Associates reports new findings from research on more efficient and effective methods to treat asthma. Houston, TX (PRWEB) February
A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.
Novartis has announced positive results from a Phase III clinical study, which showed that Xolair, a treatment for allergic asthma in adolescents and adults, significantly reduced asthma attacks in children aged six to 11 years with uncontrolled moderate-to-severe persistent allergic asthma.
By Amy Norton NEW YORK (Reuters Health) - Children with peanut allergies may be less likely to accidentally eat peanut-containing foods than in years past, but the problem still needs attention, a Canadian study suggests.
NEW YORK (Reuters Health) - Individuals with severe persistent dermatitis who fail to gain adequate control despite standard treatments may find relief with the addition of Xolair (omalizumab), according to a group of dermatologists from Georgia.